title: The role of molecular imaging in the diagnosis and management of neuropsychiatric disorders.
abstract: Neuropsychiatric disorders are becoming a major socioeconomic burden to modern society. In recent years, a dramatic expansion of tools has facilitated the study of the molecular basis of neuropsychiatric disorders. Molecular imaging has enabled the noninvasive characterization and quantification of biological processes at the cellular, tissue, and organism levels in intact living subjects. This technology has revolutionized the practice of medicine and has become critical to quality health care. New advances in research on molecular imaging hold promise for personalized medicine in neuropsychiatric disorders, with adjusted therapeutic doses, predictable responses, reduced adverse drug reactions, early diagnosis, and personal health planning. In this paper, we discuss the development of radiotracers for imaging dopaminergic, serotonergic, and noradrenergic systems and β-amyloid plaques. We will underline the role of molecular imaging technologies in various neuropsychiatric disorders, describe their unique strengths and limitations, and suggest future directions in the diagnosis and management of neuropsychiatric disorders.
authors.affiliation: Institute of Nuclear Energy Research, Lungtan, Taoyuan, Taiwan.
authors.forename: Lie-Hang
authors.initials: LH
authors.lastname: Shen
authors.forename: Yu-Chin
authors.initials: YC
authors.lastname: Tseng
authors.forename: Mei-Hsiu
authors.initials: MH
authors.lastname: Liao
authors.forename: Ying-Kai
authors.initials: YK
authors.lastname: Fu
mesh_terms: D000544:Alzheimer Disease / Q000175:diagnosis / Q000628:therapy; D006801:Humans; D001523:Mental Disorders / Q000175:diagnosis* / Q000628:therapy*; D057054:Molecular Imaging / Q000379:methods*; D019964:Mood Disorders / Q000175:diagnosis / Q000628:therapy; D010300:Parkinson Disease / Q000175:diagnosis / Q000628:therapy